Feedback
Settings

Settings

Goto Application

14,224 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,423
1.WO/2026/099721METHOD FOR BACTERIOPHAGE PRODUCTION
WO - 15.05.2026
Int.Class C12N 7/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
02Recovery or purification
 Appl.No PCT/IB2025/061198 Applicant NATIONAL RESEARCH COUNCIL OF CANADA Inventor PETERS, Danielle
Provided is a method for infecting a bacterium, in which a host bacterium is exposed to a phage depolymerase and a bacteriophage. The depolymerase catalyzes degradation of at least one cell-surface or extracellular polysaccharide of the host bacterium, thereby increasing the susceptibility of the host bacterium to infection by the bacteriophage. The method may be used to increase production of the bacteriophage and/or to increase the host range of the bacteriophage. Further provided is use of a phage depolymerase selected from B5, As11, TaPaz, APK2, APK37, and IME200, or a composition comprising the same, for increasing the susceptibility of an A. baumannii to infection by a bacteriophage. The A. baumannii may be an AB030, MRSN 843, MRSN 1183, MRSN 7446, MRSN 15088, MRSN 24008, MRSN 31159, MRSN 31468, or MRSN 32866 strain.
2.WO/2026/097245CRYOPROTECTANT AND USE THEREOF
WO - 15.05.2026
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/CN2024/130128 Applicant SUZHOU ROCROCK NO.1 BIOTECHNOLOGY CO., LTD. Inventor YIN, Xiushan
, and 1-10 wt % of a zwitterionic donor, wherein the mass percentage is the mass percentage in the cryoprotectant, and the concentration of the pH buffer in the cryoprotectant is greater than 0 and less than or equal to 100 mM.
3.WO/2026/102329METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO ONCOLYTIC VIROTHERAPY
WO - 15.05.2026
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
 Appl.No PCT/US2025/054658 Applicant CG ONCOLOGY, INC. Inventor SHEN, Shihpei Pearl
The present invention provides methods for selecting an individual having a solid or lymphatic tumor for treatment with an oncolytic virus, comprising determining a level of one of a coxsackie adenovirus receptor (CXADR) gene and/or a level and/or a mutation of each of one or more Rb/E2F pathway genes (e.g, E2F1, E2F2, E2F3, E2F4, E2F5, RB1, RB2, RB3, CCND1, CCND2, CCND3, CCNE1, CCNE2, CDK2, CDK4, CDK6, CDKN2A (pl6/INK4A), CDKN2B, CDKN2C, CDKN2D) in a biological sample of the individual. The present invention also provides methods of treating a solid or lymphatic tumor in an individual, comprising selecting the individual for treatment with an oncolytic virus and administering an effective amount of the oncolytic virus. The treatment method may further comprise administering an effective amount of an immunomodulator. Also provided are compositions and kits for carrying out the methods.
4.WO/2026/101828REPROGRAMMING THE GENOME OF PHAGE FOR VACCINATION AND IMMUNOTHERAPY APPLICATIONS
WO - 15.05.2026
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
 Appl.No PCT/US2025/053755 Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor BELCHER, Angela
Engineered filamentous bacteriophage particle are provided, and DNA extracted from such phage particles, including: (a) a filamentous bacteriophage capsid comprising a peptide antigen displayed on a surface of the capsid; and (b) a single stranded DNA molecule (ssDNA) encapsulated within the capsid, wherein the single stranded DNA molecule; wherein (i) the ssDNA comprises at least 12% unmethylated CG dinucleotides; (ii) the ssDNA comprises sequences encoding bacteriophage (A) fl-ori, (B) fl-term, and (C) packaging signal; and (iii) the ssDNA comprises less than 50% bacteriophage ssDNA.
5.WO/2026/096653METHODS OF TREATING NON-MUSCLE INVASIVE BLADDER CANCER
WO - 07.05.2026
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
 Appl.No PCT/US2025/053143 Applicant CG ONCOLOGY, INC. Inventor KASTURI, Vijay K.
The present invention provides methods for treating an individual having intermediate-risk non-muscle invasive bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating intermediate-risk non-muscle invasive bladder cancer.
6.WO/2026/090050USE OF INVERTED TERMINAL REPEATS (ITRS) AND ITR-PROXIMAL REGION (IPRS) IN GENE THERAPY VECTORS
WO - 30.04.2026
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/US2025/051657 Applicant UNIVERSITY OF MASSACHUSETTS Inventor GAO, Guangping
In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeat (ITR) proximal regions (IPRs). In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.
7.WO/2026/082715MACROPHAGE DEPLETION AND VESICULAR STOMATITIS VIRUS FOR TREATMENT OF CANCER
WO - 23.04.2026
Int.Class A61K 35/766
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
766Rhabdovirus, e.g. vesicular stomatitis virus
 Appl.No PCT/EP2025/079590 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor MAYR, Melissa
The present invention relates to the treatment of cancers and in particular to the treatment of cancers with a macrophage depleting agent and a recombinant vesicular stomatitis virus.
8.20260108570BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
US - 23.04.2026
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
 Appl.No 19100379 Applicant THE UNIVERSITY OF CHICAGO Inventor Mark MIMEE

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more isolated bacteriophage comprising a bacterio-phage sequence that is at least 99% identical to any one of SEQ ID NO:1-74. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic Klebsiella infection.

9.WO/2026/085129HIGH-DOSE GAD GENE THERAPY FOR TREATING PARKINSON'S DISEASE
WO - 23.04.2026
Int.Class A61K 38/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
 Appl.No PCT/US2025/050923 Applicant MEIRAGTX NEURO I, LLC Inventor FORBES, Alexandria
Provided herein are compositions and methods for treating or preventing neurodegenerative disease and for treating or preventing symptoms associated with neurodegenerative disease, including Parkinson's disease. For example, provided are methods of treating a patient with Parkinson's disease, the method comprising administering to the patient vectors comprising a nucleic acid encoding glutamic acid decarboxylase (GAD).
10.WO/2026/085510COMPOSITIONS COMPRISING AN ONCOLYTIC VIRUS AND A GLIAL CELL FOR USE IN TREATING NEUROBLASTOMA
WO - 23.04.2026
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
 Appl.No PCT/US2025/051577 Applicant IMMUNOLUX INTERNATIONAL CORP. Inventor SZALAY, Aladar A.
Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and/or astrocytes) and/or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.
# -